MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Kura Oncology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

6.54 2.99

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.23

Max

6.54

Pagrindiniai rodikliai

By Trading Economics

Pajamos

35M

-19M

Pardavimai

54M

54M

Pelnas, tenkantis vienai akcijai

-0.22

Pelno marža

-35.664

Darbuotojai

192

EBITDA

43M

-17M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+311.44% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-01

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-43M

570M

Ankstesnė atidarymo kaina

3.55

Ankstesnė uždarymo kaina

6.54

Naujienos nuotaikos

By Acuity

40%

60%

146 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Kura Oncology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-02 23:55; UTC

Karštos akcijos

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2025-04-02 22:50; UTC

Pagrindinės rinkos jėgos

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2025-04-02 21:08; UTC

Uždarbis

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2025-04-02 21:00; UTC

Uždarbis

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2025-04-02 23:56; UTC

Rinkos pokalbiai

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2025-04-02 23:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-02 23:44; UTC

Rinkos pokalbiai

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2025-04-02 23:44; UTC

Svarbiausios naujienos

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2025-04-02 23:32; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-04-02 23:32; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-02 23:32; UTC

Rinkos pokalbiai

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2025-04-02 23:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-02 23:12; UTC

Rinkos pokalbiai

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2025-04-02 23:10; UTC

Rinkos pokalbiai

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2025-04-02 23:09; UTC

Rinkos pokalbiai

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2025-04-02 23:09; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-04-02 22:57; UTC

Rinkos pokalbiai

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2025-04-02 22:56; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-04-02 22:56; UTC

Rinkos pokalbiai

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2025-04-02 22:43; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2025-04-02 22:12; UTC

Rinkos pokalbiai

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2025-04-02 21:48; UTC

Svarbiausios naujienos

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2025-04-02 21:41; UTC

Rinkos pokalbiai

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2025-04-02 21:17; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-04-02 21:17; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-02 21:17; UTC

Rinkos pokalbiai

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2025-04-02 21:04; UTC

Svarbiausios naujienos

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2025-04-02 21:03; UTC

Rinkos pokalbiai

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2025-04-02 20:53; UTC

Uždarbis

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2025-04-02 20:52; UTC

Uždarbis

Kaiser Aluminum Changes Inventory Acctg Methodology

Akcijų palyginimas

Kainos pokytis

Kura Oncology Inc Prognozė

Kainos tikslas

By TipRanks

311.44% į viršų

12 mėnesių prognozė

Vidutinis 26.25 USD  311.44%

Aukščiausias 40 USD

Žemiausias 10 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Kura Oncology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

12

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

6.27 / 7.14Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

146 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.